Variable | Surgical approach | Standardised differences | ||
---|---|---|---|---|
TaTME, No. (%) | LapTME, No. (%) | Before IPTW | After IPTW | |
Total, No. | 344 | 366 | ||
Center | ||||
Barcelona | 194 (56.4) | 212 (57.9) | 0.1189 | 0.1238 |
Gelderse Vallei | 90 (26.1) | 79 (21.5) | ||
AMC | 60 (17.4) | 75 (20.4) | ||
Age, years (mean, 95% CI) | 66.5 (65.2–67.7) | 66.4 (65.2–67.6) | 0.0071 | < 0.0001 |
Gender | ||||
Female | 104 (30.2) | 137 (37.4) | 0.1526 | −0.007 |
Male | 240 (69.7) | 229 (62.5) | ||
ASA | ||||
I | 44 (12.7) | 68 (18.5) | 0.0682 | 0.0002 |
II | 239 (69.4) | 227 (62.0) | ||
III | 61 (17.7) | 71 (19.4) | ||
BMI, kg/m2(mean, 95% CI) | 25.5 (25.1–25.9) | 26.4 (25.7–27.0) | −0.161 | −0.017 |
Distance from AV, cm (mean, 95% CI) | 7.2 (6.9–7.5) | 6.5 (6.1–6.8) | 0.2487 | 0.0024 |
Clinical T-stage | ||||
cT1 | 0 (0.0) | 4 (1.1) | 0.0726 | 0.0047 |
cT2 | 27 (7.8) | 41 (11.8) | ||
cT3 | 289 (84.0) | 266 (76.6) | ||
cT4 | 28 (8.1) | 35 (10.0) | ||
Clinical N-stage | ||||
cN0 | 148 (43.0) | 113 (30.8) | −0.288 | 0.0005 |
cN1 | 155 (45.0) | 181 (49.4) | ||
cN2 | 41 (11.9) | 72 (19.6) | ||
Baseline threatened/involved CRM | 94 (27.3) | 101 (27.6) | −0.006 | −0.009 |
Pathologic response to NATa | ||||
TRG 1 | 93 (38.2) | 103 (36.5) | −0.144 | −0.003 |
TRG 2 | 76 (31.2) | 85 (30.1) | ||
TRG 3 | 74 (30.4) | 94 (33.3) | ||
Pathological T-stage | −0.144 | −0.003 | ||
pT0 | 40 (11.6) | 35 (9.5) | −0.144 | −0.003 |
pTis | 1 (0.2) | 0 (0.0) | ||
pT1 | 26 (7.5) | 20 (5.4) | ||
pT2 | 85 (24.7) | 95 (25.9) | ||
pT3 | 179 (52.0) | 179 (48.9) | ||
pT4 | 13 (3.7) | 37 (10.1) | ||
Pathological N-stage | ||||
pN0 | 251 (72.9) | 243 (66.3) | −0.144 | −0.003 |
pN1 | 57 (16.5) | 76 (20.7) | ||
pN2 | 33 (9.5) | 47 (12.8) | ||
Variable | Surgical approach | Standardised differences | ||
TaTME, No. (%) | LapTME, No. (%) | Before IPTW | After IPTW | |
pN3 | 0 (0.0) | 0 (0.0) | ||
pN1c | 3 (0.8) | 0 (0.0) | ||
Sphincter saving surgeryb | 334 (97.0) | 272 (74.3) | NA | NA |